Liver transplantation: An update 2007

Current Opinion in Gastroenterology

Volumn 23, Issue 3, 2007, Pages 292-298

  Said, Adnan ^a   Einstein, Michael ^a   Lucey, Michael R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Hepatitis C; Hepatocellular carcinoma; Liver transplant; Model for end stage liver disease; Renal failure

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

ADJUVANT THERAPY; ALCOHOL LIVER DISEASE; CLINICAL TRIAL; DISEASE COURSE; FIRST AID; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; MONOTHERAPY; OUTCOME ASSESSMENT; REVIEW;

GRAFT SURVIVAL; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 34147126527     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3280f9df41     Document Type: Review

References (70)

1. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864-871.
2. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91-96.
3. Kanwal F, Dulai GS, Spiegel BM, et al. A comparison of liver transplantation outcomes in the pre vs. post-MELD eras. Aliment Pharmacol Ther 2005; 21:169-177.
4. Yoo HY, Thuluvath PJ. Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States. Liver Int 2005; 25:536-541.
5. Bajaj JS, Saeian K. MELD score does not discriminate against patients with hepatic encephalopathy. Dig Dis Sci 2005; 50:753-756.
6. Freeman RB, Wiesner RH, Edwards E, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10:7-15.
7. Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6:2651-2659. • This review of UNOS data audits the impact of preoperative renal dysfunction on posttransplant outcomes in the MELD era.
8. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802-810.
9. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32-39.
10. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130:1652-1660. • This study proposes a MELD alteration that adds serum sodium to the current MELD formula.
11. Londono MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130:1135-1143. • This study examines the influence of pretransplant hyponatremia on posttransplant complications.
12. Jacob M, Copley LP, Lewsey JD, et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland. Liver Transpl 2004; 10:903-907.
13. Onaca NN, Levy MF, Sanchez EQ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003; 9:117-123.
14. Haydon GH, Hiltunen Y, Lucey MR, et al. Self-organizing maps can determine outcome and match recipients and donors at orthotopic liver transplantation. Transplantation 2005; 79:213-218.
15. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis 2004; 17:363-371.
16. Terrault NA. Treatment of recurrent hepatitis C in liver transplant recipients. Clin Gastroenterol Hepatol 2005; 3 (10 Suppl 2):S125-S131.
17. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-355.
18. Wiesner RH, Sorrell M, Villamil F. Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C. Liver Transpl 2003; 9:S1-S9.
19. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6:1586-1599. •• A good systematic review of interferon-based antiviral therapy after liver transplantation.
20. Ercolani G, Grazi GL, Ravaioli M, et al. Histological recurrent hepatitis C after liver transplantation: outcome and role of retransplantation. Liver Transpl 2006; 12:1104-1111. • This paper delineates which patients with recurrent HCV after primary transplantation fare poorly.
21. Smith MW, Walters KA, Korth MJ, et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006; 130:179-187.
22. Feucht HE. Significance of donor-specific antibodies in acute rejection. Transplant Proc 2005; 37:3693-3694.
23. Schmeding M, Dankof A, Krenn V, et al. C4d in acute rejection after liver transplantation - a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6:523-530. • A paper that examines tissue staining with C4d to differentiate acute cellular rejection from HCV recurrence in the allograft.
24. Jain A, Mohanka R, Orloff M, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in postliver transplant biopsies. Clin Transplant 2006; 20:624-633.
25. Lorho R, Turlin B, Aqodad N, et al. C4d: a marker for hepatic transplant rejection. Transplant Proc 2006; 38:2333-2334.
26. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38:34-41.
27. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-231.
28. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
29. Lake JR, Shorr JS, Steffen BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5:549-557.
30. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823-830.
31. Bahra M, Neumann UP, Jacob D, et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc 2005; 37:1700-1702.
32. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202-210.
33. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10:1240-1247.
34. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006; 12:1496-1503. • A paper that examines the effect of changing donor age by era on the progression of fibrosis in HCV-positive transplant recipients.
35. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42:448-456.
36. Kornberg A, Kupper B, Tannapfel A, et al. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol 2005; 5:107-115.
37. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12:51-57. • An intriguing study that shows possible antiviral effect of cyclosporine in vitro and increased efficacy of interferon when cyclosporine is the primary immunosuppressant.
38. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
39. Stangl JR, Carroll KL, Illichmann M, Striker R. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004; 77:562-567.
40. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11:386-395.
41. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65:1044-1046.
42. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10:1258-1262.
43. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699.
44. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30:1434-1440.
45. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080-1086.
46. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394-1403.
47. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12:1761-1769. • A large retrospective study that examines the impact of the UCSF criteria on patient survival after transplant for HCC.
48. Lesurtel M, Mullhaupt B, Pestalozzi BC, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6:2644-2650. •• A good systemic review that examines the impact of TACE on patients with HCC undergoing liver transplant.
49. Kim do Y, Choi MS, Lee JH, et al. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol 2006; 12:6992-6997.
50. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13:272-279.
51. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
52. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9:741-747.
53. Cohen AJ, Stegall MD, Rosen CB, et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002; 8:916-921.
54. Neau-Cransac M, Morel D, Bernard PH, et al. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002; 16:368-373.
55. Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5:1111-1119.
56. Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21:478-482.
57. Beckebaum S, Cicinnati VR, Klein CG, et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 2004; 36:2671-2674.
58. Kornberg A, Kupper B, Hommann M, Scheele J. Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol 2005; 5:141-146.
59. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75:186-190.
60. Cantarovich M, Tzimas GN, Barkun J, et al. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003; 76:98-102.
61. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11:1064-1072.
62. Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999; 5:414-420.
63. Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69:1886-1890.
64. Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69:307-311.
65. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357:609-610.
66. Ziolkowski J, Paczek L, Senatorski G, et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003; 35:2307-2309.
67. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9:126-129.
68. DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 2006; 12:813-820. •• An excellent long term study that describes a cohort of ALD liver transplant recipients and systematically records their alcohol use patterns.
69. Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2007; 13:197-205.
70. Weinrieb RM, Van Horn DH, McLellan AT, Lucey MR. Interpreting the significance of drinking by alcohol-dependent liver transplant patients: fostering candor is the key to recovery. Liver Transpl 2000; 6:769-776.